Von Willebrand’s Disease Pipeline Summary

DelveInsight’s, “Von Willebrand’s Disease - Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Von Willebrand’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Von Willebrand’s Disease: Understanding

Von Willebrand’s Disease: Overview

Von Willebrand disease (VWD) is a common inherited or acquired bleeding disorder caused by a quantitative deficiency or qualitative defect of von Willebrand factor (VWF), a glycoprotein essential for normal hemostasis. VWF is produced primarily by endothelial cells and megakaryocytes and functions both as a mediator of platelet adhesion at sites of vascular injury and as a carrier that stabilizes coagulation factor VIII. Deficiency or dysfunction of VWF therefore results in impaired primary hemostasis and, in some cases, reduced factor VIII levels, leading to an increased tendency for bleeding.

VWD may be inherited or acquired. Inherited VWD is classified into three major types: Type 1, the most common form, results from a partial quantitative deficiency of VWF; Type 2 results from qualitative defects in VWF and includes subtypes 2A, 2B, 2M, and 2N; and Type 3 is the most severe form, characterized by an almost complete or complete absence of VWF and an autosomal recessive inheritance pattern. Acquired VWD can develop secondary to conditions such as malignancies, lymphoproliferative disorders, autoimmune diseases, hypothyroidism, myeloproliferative neoplasms, and high-flow cardiovascular states.

VWF is a large multimeric glycoprotein synthesized by endothelial cells and megakaryocytes. Following vascular injury, VWF facilitates platelet adhesion to the damaged vessel wall, thereby contributing to primary hemostasis. Larger VWF multimers have greater hemostatic activity and provide more binding sites for platelets and endothelial components. VWF also protects factor VIII from degradation, thereby maintaining its circulating levels. In VWD, reduced VWF quantity or impaired VWF function compromises platelet adhesion and may increase factor VIII degradation, resulting in prolonged bleeding. The specific defect and severity vary according to the VWD subtype.

Diagnosis of VWD is based on the patient's bleeding history together with laboratory evaluation. Common clinical manifestations include recurrent or excessive bruising, prolonged bleeding following minor trauma or dental procedures, epistaxis, and heavy menstrual bleeding. Initial laboratory assessment includes a complete blood count and coagulation profile; platelet counts are generally normal, prothrombin time (PT) is usually normal, while activated partial thromboplastin time (aPTT) may be prolonged because of reduced factor VIII levels.

Treatment depends on the VWD subtype, disease severity, bleeding episode, and clinical setting. Desmopressin (DDAVP) is commonly used in Type 1 VWD and selected Type 2 subtypes because it stimulates the release of stored VWF from endothelial cells, thereby increasing VWF and factor VIII levels. Patients with Type 3 VWD or severe VWD who do not respond adequately to DDAVP may require VWF replacement therapy, including VWF-containing factor VIII concentrates, particularly during major bleeding, trauma, or surgery. Tranexamic acid, an antifibrinolytic agent, may be used to control mucosal bleeding by reducing fibrin clot breakdown.

"Von Willebrand’s Disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Von Willebrand’s Disease pipeline landscape is provided which includes the disease overview and Von Willebrand’s Disease treatment guidelines. The assessment part of the report embraces, in depth Von Willebrand’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Von Willebrand’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Von Willebrand’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Von Willebrand’s Disease.

Von Willebrand’s Disease Emerging Drugs Chapters

This segment of the Von Willebrand’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Von Willebrand’s Disease Emerging Drugs

• VGA039: Incyte

VGA039 (latarcibart) is an investigational monoclonal antibody therapy with a novel mechanism of action that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. Latarcibart has the potential to be a universal prophylactic therapy for numerous bleeding disorders, starting with all types of von Willebrand disease (VWD) and bleeding sites. As a subcutaneously self-administered investigational antibody therapy with a once monthly dosing regimen, latarcibart has the potential to improve bleeding outcomes, convenience, and quality of life for patients. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Von Willebrand’s Disease.

Further product details are provided in the report……..

Von Willebrand’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Von Willebrand’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Von Willebrand’s Disease

There are approx. 4+ key companies which are developing the therapies Von Willebrand’s Disease. The companies which have their Von Willebrand’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Incyte, and others.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Von Willebrand’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Von Willebrand’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Von Willebrand’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Von Willebrand’s Disease drugs.

Von Willebrand’s Disease Report Insights

• Von Willebrand’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Von Willebrand’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Von Willebrand’s Disease drugs?
• How many Von Willebrand’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Von Willebrand’s Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Von Willebrand’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Von Willebrand’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte
• Alnylam Pharmaceuticals

Key Products

• VGA039 (Latarcibart)
• ALN 6400